| |
SGLT2+GLP1+Finerenone Improves Kidney, Diabetes CVD Outcomes/Mortality
|
| |
| |
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
march 2026
Download the PDF here
Download the PDF here
the greatest acute eGFR decline was observed when participants were treated with finerenone, SGLT-2i, and GLP-1RA.
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
feb 2024
Download the PDF here
Download the PDF here
Compared with conventional care, the combination of SGLT2i, GLP-1 RA, and ns-MRA was associated with a hazard ratio of 0.65 (95% CI, 0.55-0.76) for major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death).
There were also projected gains in survival free from hospitalized heart failure (3.2 years [95% CI, 2.4-4.0]), chronic kidney disease progression (5.5 years [95% CI, 4.0-6.7]), cardiovascular death (2.2 years [95% CI, 1.2-3.0]), and all-cause death (2.4 years [95% CI, 1.4-3.4]).
CONCLUSIONS:
In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment of SGLT2i, GLP-1 RA, and ns-MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival.
|
|
| |
| |
|
|
|
